XOMA (XOMAP) Stock Price, News & Analysis

Company Overview

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $25.61 to $25.70
• 50-Day Range: $25.39 to $26.07
• 52-Week Range: $24.96 to $26.51
• Volume: 1,005 shs
• Average Volume: 1,691 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 8.44%
• Price Target: N/A
• Consensus Rating: N/A

XOMAP Stock Analysis - Frequently Asked Questions

How have XOMAP shares performed this year?

XOMA's stock was trading at $25.88 at the start of the year. Since then, XOMAP stock has decreased by 1.1% and is now trading at $25.5910.

How do I buy shares of XOMA?

Shares of XOMAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Record date for 7/15 Dividend: 7/03/2025
• Ex-Dividend for 7/15 Dividend: 7/03/2025
• Dividend Payable: 7/15/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XOMAP
• CIK: 791908
• Web: www.xoma.com
• Phone: 510-204-7200
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $13.05 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A